This segment focuses on the development, manufacturing, and commercialization of treatments for opioid use disorder (OUD). The primary product in this segment is Buvidal (buprenorphine), a long-acting injectable medication. Research and development activities include ongoing clinical trials to expand the indications and improve the formulation of Buvidal. The technology used is based on the FluidCrystal® drug delivery platform, which allows for sustained release of the active ingredient. The patient impact is significant, as Buvidal offers a convenient and effective treatment option for individuals struggling with OUD, improving adherence and reducing the risk of relapse. Market positioning is strong, with Buvidal gaining market share in several regions. Future opportunities include expanding into new markets and exploring combination therapies. Regulatory aspects involve obtaining and maintaining marketing authorizations in various countries. Partnerships and collaborations are crucial for distribution and market access.

This segment concentrates on the development of treatments for endocrine disorders, particularly acromegaly and neuroendocrine tumors. The lead product candidate is CAM2029, a long-acting injectable formulation of octreotide. Research and development efforts include Phase III clinical trials for acromegaly and neuroendocrine tumors, as well as Phase II trials for polycystic liver diseases. The technology platform is based on the FluidCrystal® drug delivery system, designed to provide sustained release of octreotide. The patient impact is substantial, as CAM2029 aims to improve the management of symptoms and quality of life for patients with these conditions. Market positioning is competitive, with the potential to offer a more convenient and effective treatment option. Future opportunities include expanding the indications for CAM2029 and exploring combination therapies. Regulatory aspects involve navigating the approval processes in various regions. Partnerships and collaborations are essential for clinical trial execution and commercialization.

This segment is dedicated to the development of treatments for chronic pain conditions. The primary focus is on CAM2038, a long-acting injectable buprenorphine formulation. Research and development activities include clinical trials to evaluate the efficacy and safety of CAM2038 in various chronic pain settings. The technology utilized is the FluidCrystal® drug delivery platform, which enables sustained release of buprenorphine. The patient impact is significant, as CAM2038 aims to provide effective pain relief with a reduced risk of misuse and diversion. Market positioning is competitive, with the potential to offer a valuable alternative to existing pain medications. Future opportunities include expanding the indications for CAM2038 and exploring combination therapies. Regulatory aspects involve obtaining and maintaining marketing authorizations. Partnerships and collaborations are important for clinical trial execution and commercialization.